Legend Biotech Corporation (NASDAQ:LEGN) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET
Company Participants
Jessie Yeung – Vice President of Investor Relations and Finance
Ying Huang – Chief Executive Officer
Lori Macomber – Chief Financial Officer
Mythili Koneru – Chief Medical Officer
Steve Gavel – Senior Vice President, Commercial Development, U.S. & Europe
Conference Call Participants
Gena Wang – Barclays
Kelly Shi – Jefferies
Jessica Fye – JPMorgan
Kostas Biliouris – BMO Capital
James Shin – DB
Vikram Purohit – Morgan Stanley
Mitchell Kapoor – H.C. Wainright
Rick Bienkowski – Cantor Fitzgerald
Sean McCutcheon – Raymond James
Operator
Ladies and gentlemen, thank you for standing by. Welcome to Legend Biotech Reports Third Quarter 2024 Financial Results. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions]. Please be advised that today’s conference is being recorded.
I would like now to turn the conference to Jessie Yeung, Vice President of Investor Relations and Finance. Please go ahead.
Jessie Yeung
Good morning. This is Jessie Yeung, VP of Investor Relations and Finance. Thank you for joining our call today to review our third quarter performance. Joining me on today’s call are Ying Huang, the company’s Chief Executive Officer; and Lori Macomber, the company’s Chief Financial Officer. Following the prepared remarks, we will open up the call for Q&A. We have our Chief Medical Officer, Mythili Koneru; and our SVP of Commercial Development, Steven Gavel, joining the Q&A session.
During today’s call, we will be making forward-looking statements, which are subject to risks and uncertainties that may cause our actual results to differ materially from those expressed or implied here within. These forward-looking statements are discussed in greater detail in our SEC filings, which we encourage you to read and can be
